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randomized controlled trialsUmberto Benedetto, MD, Emiliano Angeloni, MD, Simone Refice, MD, and Riccardo Sinatra, MD,
Rome, ItalyThe excellent patency rate achieved with the internal tho-
racic artery in coronary artery bypass grafting (CABG)
prompted cardiac surgeons to explore other arteries as sec-
ond conduits instead of the saphenous vein graft (SVG). Ini-
tially described in 1973 by Carpentier and colleagues,1 the
radial artery (RA) was soon abandoned as a bypass graft
because reports documented dismal early angiographic
outcomes. Because of improvements in graft-harvesting
techniques and the use of postoperative calcium-channel
blocker therapy to prevent early vasospasm, the RA is newly
popular as a second conduit in association with the left inter-
nal thoracic artery. However, concerns about the high inci-
dence of RA graft failure caused by a compromised flow
state continue to be raised. Thus ongoing debate remains
regarding the superiority of the RA as an aortocoronary
conduit over the SVG, which continues to be widely used
as a second conduit.
Therefore, we conducted a meta-analysis on available ran-
domized controlled trials (RCTs) to evaluate whether the RA
is associated with a better patency rate when compared with
the SVG as a second conduit in CABG.
CLINICAL SUMMARY
All RCTs comparing results of RA versus SVG graft pa-
tency rates after CABG were identified by using a 2-level
search strategy. First, a public domain database (MEDLINE)
was searched by using a Web-based search engine (PubMed
and Ovid). Second, relevant studies were identified through
a manual search of secondary sources, including references
of initially identified articles and a search of reviews and
commentaries. The MEDLINE database was searched
from January 1966 to March 2009. Medical subject heading
key words included ‘‘coronary artery bypass grafting, radial
artery, saphenous vein graft’’ and ‘‘randomized controlled
trials.’’ Studies considered for inclusion met the following
criteria: the design was an RCT; patients were randomly as-
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angiographic follow-up was performed; and the graft failure
rate, including total graft occlusion and severe diffuse graft
narrowing (string sign), was reported. When several RCTs
reported on the same patient material, only the most recent
article was included. Two reviewers (UB and EA) abstracted
the data independently. For each study, data regarding RA
and SVG graft failure rates were used to generate event rates
for RA and SVG failure and risk difference (<0 favors the
RA and>0 favors the SVG). The 95% confidence intervals
(CIs) were based on the asymptotic normality of the com-
bined estimates. A pooled summary effect estimate was cal-
culated by means of a random effects model. Between-study
heterogeneity was analyzed by using the I2 index. Metare-
gression (methods of moments) was used to investigate the
effect of time to follow-up angiographic analysis on graft
failure risk. Publication bias was evaluated by using the
Begg and Mazumdar rank correlation test.
Our research identified 5 RCTs including a total of 936
patients randomly assigned to receive an RA or SVG as
a second conduit. The article by Gaudino and associates2
reported 2 RCTs including patients with previous percutane-
ous coronary stent implantation before surgical intervention
with preoperative angiographic demonstration of a failed
(I trial) or patent (II trial) intracoronary stent. Desai and co-
workers3 randomly assigned the RA to bypass the major
vessel in either the inferior territory or the lateral territory,
with the SVG used for the opposing territory (control). Gau-
dino and associates2 and Collins and coworkers4 randomly
assigned the RA and SVG to bypass the major vessel in
the lateral territory. Finally, Buxton and colleagues5 ran-
domly assigned the RA and SVG to bypass the largest avail-
able coronary artery other than the left anterior descending
artery.
Follow-up angiographic analysis was performed in 669
(71.4%) of 936 patients, allowing us to compare the graft pa-
tency of 563 RAs versus 546 SVGs. Mean time to follow-up
angiographic analysiswas 22months (range, 10–52months).
Pooled analysis showed that cumulative graft failure
rates were 14.1% (95% CI, 11.4% to 17.4%; P <
.001) and 14.6% (95% CI, 11.8% to 17.8%; P< .001)
for the RA and SVG, respectively (Figure 1), with no sig-
nificant advantage for the RA (risk difference,0.40; 95%
CI,0.128 to 0.048; P ¼ .372; Figure 2). Time to follow-
up angiographic analysis did not significantly influence
graft failure risk (P ¼ .42, Figure 2). No publication biases
were found (P ¼ .14).rdiovascular Surgery c Volume 139, Number 1 229
FIGURE 1. Right, Radial artery (RA) failure rates of individual trials (squares) and the pooled summary effect estimate (diamond)with its 95% confidence
interval (CI). Left, Saphenous vein graft (SVG) failure rates of individual trials (squares) and the pooled summary effect estimate (diamond) with its 95%
confidence interval (CI).
Brief Research ReportsDISCUSSION
The RA is widely believed to achieve a better graft pa-
tency rate than the SVG when grafted on coronary arteries
other than the left anterior descending artery, despite
a lack of conclusive results. To date, only 5 available
RCTs have compared RA versus SVG patency. The study
by Desai and coworkers,3 which included the largest number
of patients, showed the RA having a reduced total graft oc-
clusion rate but a significantly higher rate of graft failureFIGURE 2. Right, Risk difference for radial artery (RA) versus saphenous vein
indicates the pooled summary effect estimate with its 95% confidence interval (
analysis on estimated risk differences. Circles indicate individual trials.
230 The Journal of Thoracic and Cardiovascular Surgcaused by severely compromised flow state (string sign).
The present meta-analysis, pooling data from RCTs, found
the RA and SVG to have similar graft failure rates, and these
results were not influenced by follow-up time.
In conclusion, no definitive evidence supports the superi-
ority of the RA over the SVG in terms of graft failure rate in
patients undergoing CABG. This result is primarily dictated
by the RA’s high incidence of severely impaired flow state,
probably related to its marked vasal reactivity.graft (SVG) failure rate. Squares indicate individual trials, and the diamond
CI). Left, Meta-regression analysis of time to follow-up (FU) angiographic
ery c January 2010
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ized trial. J Thorac Cardiovasc Surg. 2003;125:1363-71.Cost of thoracic endovascular aortic repair versus open repair and
implications for the US health care systemKaren L. Walker, BA, MHS, Paul Lipori, BA, MBA,W. Anthony Lee, MD, and Thomas Mark Beaver, MD,
Gainesville, FlaTABLE 1. Patient demographics and comorbidities in comparison
groups TEVAR versus open repair
TEVAR Open repair P value
Age 73.21 62.28 <.001
Female 42.86% (12/28) 34.48% (10/29) .516
Hypertension 78.57% (22/28) 89.66% (26/29) .251
Coronary artery
disease
32.14% (9/28) 27.59% (8/29) .707
COPD 42.86% (12/28) 20.69% (6/29) .072
CKD 0% (0/28) 17.24% (5/29) .052
TEVAR,Thoracic endovascular aortic repair;COPD, chronic obstructive pulmonary dis-
ease; CKD, chronic kidney disease.Following the 2005 FDA approval of the TAG endograft
(W. L. Gore & Associates, Inc, Flagstaff, Ariz), thoracic
endovascular aortic repair (TEVAR) utilization increased
dramatically.1 The clinical trial leading to approval of the
Gore-TAG thoracic stent graft demonstrated beneficial ef-
fects for early morbidity and mortality, with similar long-
term survival compared with open repair.2 However, there
remains a paucity of data comparing the costs of TEVAR
versus open repair. This study compared hospital costs and
physician relative value units (RVUs) between TEVAR
and open repair at a US academic institution.METHODS
Records from patients undergoing elective TEVAR and open repair of
distal arch and proximal descending thoracic aneurysms between January
2005 and December 2007 at a single academic institution were analyzed.
The hospital cost accounting system was used to compare mean costs in
the following categories: total hospitalization, total day of surgery, operat-
ing room, grafts, anesthesia, imaging, pharmacy, laboratory, and respira-
tory services. Costs were adjusted to 2007 dollars using the consumer
price index. Cost ratios are reported because hospital restrictions pro-
hibited reporting actual values. Age, gender, comorbidities, length of
stay (LOS), operating room time, and physician RVUs were examined.
Student t test was used for age, RVUs, and cost category variables.
Mann-Whitney test was used for median LOS. Pearson chi-square and
Fischer exact test were used for gender and comorbidity comparisons
(v17.0 SPSS, Chicago, Ill).DISCUSSION
Twenty-nine patients having open repair and 28 patients
having TEVAR were identified. Patients having TEVAR
were older, but comorbidities were similar between groups
(Table 1). Despite shorter surgical times for TEVAR (168
vs 465 minutes, P< .001), TEVAR operating room costs
were 2.03 times greater than open repair (P< .001). In-
creased operating room costs for TEVAR were secondary
to TEVAR graft costs, which were 22.2 times higher than
open repair. TEVAR grafts accounted for 74% of TEVAR
day of surgery costs, which were 1.32 times higher than
open repair (Figure 1). However, the total hospitalization
costs remained 1.55 times greater for open repair versus
TEVAR. Longer median LOS for open repair (20 days vs
6 days, P< .001) led to greater utilization of hospital ser-
vices. Anesthesia costs were 4.00 times greater for open
repair versus TEVAR (P< .001). Overall imaging costs
were 1.78 times greater for open repair versus TEVAR (P¼
.023). Pharmacy costs were 5.74 times greater for open re-
pair versus TEVAR (P ¼ .001). Laboratory costs were
4.94 times greater for open repair versus TEVAR (P <
.001). Respiratory services were 4.89 times greater for
open repair versus TEVAR (P ¼ .001). Despite shorterrdiovascular Surgery c Volume 139, Number 1 231
